Cullen, Edward

2Checkpoint Therapeutics, Inc., New York, NY.

1 paper on CoChat

Most cited papers

Verified
Abstract 2078: CK-101 (RX518), a mutant-selective inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC
Qian, X., Zhu, Y.-L., Cullen, E., Niecestro, R. M., & Oliviero, J. F. (2017) · Cancer Research
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 3

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free